Dec 2025 (FY25) — Mar 3, 2026
ImmunityBio FY25 — ANKTIVA Commercial Momentum and Global Expansion
Read the full callImmunityBio (IBRX) earnings
- Jun 2026
- Dec 2025 (FY25)
- Dec 2025
ImmunityBio earnings: last reported Tue, 3 Mar 2026, for the quarter ended Dec 2025.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 51.2 | +93.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -120.4 | +149.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -230 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$10 +0.91% · +$0.09
Performance +298.4% 1Y
1Y: $2.51 on 14 Oct 2025 → $10. High $11.55 (24 Feb 2026), low $1.98 (30 Dec 2025).
- Previous close
- $9.91
- 52-week range
- $1.98 – $11.55
- One year
- +287.60%
Overview
- Symbol
- IBRX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
ImmunityBio earnings calls (IBRX)
Financials
What the filings say
Net profit, year on year: −149% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 6 | 8 | 17 | 26 | 32 | 38 | 44 | 51 |
| Expenses | 86 | 77 | 81 | 98 | 88 | 103 | 114 | 113 |
| Operating profit | -80 | -69 | -64 | -71 | -56 | -65 | -70 | -62 |
| Operating margin | −1314.3% | −919.0% | −390.1% | −269.8% | −173.5% | −168.9% | −157.9% | −120.4% |
| Other income | -5 | 10 | -65 | -21 | -12 | 3 | -563 | -169 |
| Interest | 29 | 26 | 15 | 15 | 15 | 15 | — | — |
| Profit before tax | -86 | -59 | -130 | -92 | -67 | -62 | -633 | -230 |
| Tax rate | 0.0% | 0.0% | 0.2% | −0.3% | 0.1% | 0.2% | 0.0% | 0.0% |
| Net profit | -86 | -59 | -130 | -93 | -67 | -62 | -633 | -230 |
| EPS ($ per share) | -0.12 | — | -0.15 | -0.10 | -0.07 | — | -0.62 | -0.22 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -595 | -662 | -1,615 | -1,962 | -2,378 | -2,962 | -3,375 | -3,727 |
| Total liabilities | 36 | 22 | 340 | 713 | 812 | 1,090 | 871 | 1,001 |
| Fixed assets | 77 | 61 | 73 | 83 | 144 | 146 | 137 | 114 |
| Investments | — | — | 61 | 136 | 3 | 1 | 6 | 154 |
| Total assets | 182 | 143 | 221 | 469 | 362 | 504 | 383 | 502 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -63 | -152 | -172 | -274 | -338 | -367 | -391 | -305 |
| Cash from investing | 57 | 19 | -20 | -85 | 27 | -30 | -12 | -150 |
| Cash from financing | -1 | 114 | 151 | 505 | 234 | 558 | 282 | 400 |
| Net cash flow | — | -19 | -41 | 146 | -76 | 161 | -122 | -54 |
| Capital expenditure | -13 | -4 | -2 | -34 | -78 | -31 | -7 | -4 |
| Free cash flow | -76 | -156 | -173 | -308 | -416 | -397 | -398 | -309 |
IBRX revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Reportable | — | — | 100% | 100% | 100% | 100% | 100% | 100% | +93.9% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- Europe 1% ↑ 1 pt
As IBRX cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
51 filings between Dec 31, 2025 and Oct 5, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$9.51M
16 sales by 3 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 23
- Option exercise — converted options into shares
- 11
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 conversion.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Simon Barry J. | — | $4.41M | Oct 5, 2026 |
| Selecky Christobel | — | $3.00M | Jul 1, 2026 |
| Cohen Cheryl | — | $2.10M | Oct 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Simon Barry J. Director | Sale 10b5-1 plan | 25,000 | $268.8K |
| Oct 2, 2026 | Cohen Cheryl Director | Option exercise 10b5-1 plan | 55,979 | $166.8K |
| Oct 2, 2026 | Cohen Cheryl Director | Sale 10b5-1 plan | 81,056 | $851.1K |
| Jul 2, 2026 | Cohen Cheryl Director | Sale 10b5-1 plan | 131,210 | $1.25M |
| Jul 2, 2026 | Cohen Cheryl Director | Option exercise 10b5-1 plan | 55,979 | $166.8K |
| Jul 1, 2026 | Selecky Christobel Director | Sale 10b5-1 plan | 159,478 | $1.44M |
| Jul 1, 2026 | Selecky Christobel Director | Option exercise 10b5-1 plan | 35,064 | $104.5K |
| Jul 1, 2026 | Selecky Christobel Director | Option exercise 10b5-1 plan | 124,414 | $372.0K |
| Jun 30, 2026 | Selecky Christobel Director | Sale 10b5-1 plan | 1,000 | $9.0K |
| Jun 30, 2026 | Selecky Christobel Director | Option exercise 10b5-1 plan | 700 | $2.1K |
| Jun 30, 2026 | Selecky Christobel Director | Option exercise 10b5-1 plan | 300 | $897 |
| Jun 29, 2026 | Selecky Christobel Director | Sale 10b5-1 plan | 95,722 | $862.2K |
| Jun 29, 2026 | Selecky Christobel Director | Option exercise 10b5-1 plan | 32,173 | $95.9K |
| Jun 29, 2026 | Selecky Christobel Director | Option exercise 10b5-1 plan | 30,000 | $85.2K |
| Jun 29, 2026 | Selecky Christobel Director | Option exercise 10b5-1 plan | 33,549 | $100.3K |
| Jun 24, 2026 | Simon Barry J. Director | Sale 10b5-1 plan | 25,000 | $196.9K |
| Jun 4, 2026 | Simon Barry J. Director | Sale 10b5-1 plan | 23,033 | $165.3K |
| Mar 31, 2026 | SOON-SHIONG PATRICK See remarks | Conversion | 4,606,596 | $25.00M |
| Feb 24, 2026 | Simon Barry J. Director | Sale 10b5-1 plan | 75,000 | $900.8K |
| Feb 23, 2026 | Selecky Christobel Director | Sale 10b5-1 plan | 25,000 | $250.0K |
| Feb 23, 2026 | Simon Barry J. Director | Sale 10b5-1 plan | 165,000 | $1.69M |
| Feb 23, 2026 | Selecky Christobel Director | Option exercise 10b5-1 plan | 25,000 | $74.5K |
| Feb 22, 2026 | Adcock Richard CEO & President | Option exercise | 152,439 | $0 |
| Feb 22, 2026 | Adcock Richard CEO & President | Tax withheld | 77,560 | $674.8K |
| Feb 22, 2026 | Sachs David C. Chief Financial Officer | Option exercise | 40,650 | $0 |
| Feb 22, 2026 | Sachs David C. Chief Financial Officer | Tax withheld | 20,682 | $179.9K |
| Feb 22, 2026 | SOON-SHIONG PATRICK See remarks | Option exercise | 114,329 | $0 |
| Feb 22, 2026 | Simon Barry J. Director | Option exercise 10b5-1 plan | 15,243 | $0 |
| Feb 22, 2026 | Simon Barry J. Director | Tax withheld 10b5-1 plan | 6,026 | $52.4K |
| Feb 22, 2026 | LAUER REGAN J Chief Accounting Officer | Tax withheld | 1,673 | $14.6K |
| Feb 22, 2026 | LAUER REGAN J Chief Accounting Officer | Option exercise | 4,065 | $0 |
| Feb 22, 2026 | SOON-SHIONG PATRICK See remarks | Tax withheld | 58,170 | $506.1K |
| Feb 20, 2026 | Simon Barry J. Director | Sale 10b5-1 plan | 10,000 | $92.5K |
| Feb 10, 2026 | Adcock Richard CEO & President | Tax withheld | 140,048 | $970.5K |
| Feb 10, 2026 | SOON-SHIONG PATRICK See remarks | Option exercise | 274,122 | $0 |
| Feb 10, 2026 | SOON-SHIONG PATRICK See remarks | Tax withheld | 118,560 | $821.6K |
| Feb 10, 2026 | LAUER REGAN J Chief Accounting Officer | Option exercise | 5,482 | $0 |
| Feb 10, 2026 | LAUER REGAN J Chief Accounting Officer | Tax withheld | 2,257 | $15.6K |
| Feb 10, 2026 | Adcock Richard CEO & President | Option exercise | 274,122 | $0 |
| Feb 10, 2026 | Sachs David C. Chief Financial Officer | Option exercise | 82,236 | $0 |
| Feb 10, 2026 | Sachs David C. Chief Financial Officer | Tax withheld | 42,643 | $295.5K |
| Jan 20, 2026 | Simon Barry J. Director | Sale 10b5-1 plan | 75,000 | $590.9K |
| Jan 20, 2026 | Selecky Christobel Director | Option exercise 10b5-1 plan | 25,000 | $74.5K |
| Jan 20, 2026 | Selecky Christobel Director | Sale 10b5-1 plan | 25,000 | $187.7K |
| Jan 20, 2026 | Simon Barry J. Director | Sale 10b5-1 plan | 76,967 | $503.4K |
| Jan 16, 2026 | Selecky Christobel Director | Sale 10b5-1 plan | 50,000 | $250.0K |
| Jan 16, 2026 | Selecky Christobel Director | Option exercise 10b5-1 plan | 50,000 | $149.0K |
| Dec 31, 2025 | Sachs David C. Chief Financial Officer | Tax withheld | 15,435 | $30.6K |
| Dec 31, 2025 | Adcock Richard CEO & President | Option exercise | 34,483 | $0 |
| Dec 31, 2025 | Adcock Richard CEO & President | Tax withheld | 17,510 | $34.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ImmunityBio, Inc.
Free account. Everything above stays public.
Write why you follow ImmunityBio, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading